OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A.

Financials Ouro Fino Saúde Animal Participações S.A.

Equities

OFSA3

BROFSAACNOR7

Pharmaceuticals

Market Closed - Sao Paulo Other stock markets 21:00:00 03/07/2024 BST			5-day change	1st Jan Change
18.99 ^BRL	-1.04%		-0.52%	-26.99%

05-10	Transcript : Ouro Fino Saúde Animal Participações S.A., Q1 2024 Earnings Call, May 10, 2024
05-09	Ouro Fino Saúde Animal Participações S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Valuation

Fiscal Period: December	2019	2020	2022	2023	2024	2025
Capitalization ¹	2,320	2,050	1,308	1,398	1,021	-
Enterprise Value (EV) ¹	2,558	2,219	1,308	1,526	1,155	1,172
P/E ratio	50.1 x	22.8 x	10 x	-28 x	10.2 x	9.15 x
Yield	0.44%	0.49%	-	2.36%	4.37%	7.49%
Capitalization / Revenue	3.74 x	2.81 x	-	1.34 x	0.92 x	0.85 x
EV / Revenue	4.13 x	3.04 x	-	1.47 x	1.04 x	0.98 x
EV / EBITDA	23.9 x	15.6 x	-	13 x	5.18 x	4.79 x
EV / FCF	120,343,052 x	23,278,878 x	-	9,229,730 x	-	-
FCF Yield	0%	0%	-	0%	-	-
Price to Book	4.71 x	3.66 x	-	2.03 x	1.38 x	1.32 x
Nbr of stocks (in thousands)	53,949	53,949	53,768	53,768	53,768	-
Reference price ²	43.00	38.00	24.33	26.01	18.99	18.99
Announcement Date	11/02/20	04/03/21	02/03/23	07/03/24	-	-

¹BRL in Million²BRL

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2022	2023	2024	2025
Net sales ¹	619.6	730.1	-	1,041	1,108	1,197
EBITDA ¹	107.2	142.4	-	117.2	223.1	244.7
EBIT ¹	72.88	95.32	-	81.01	185.8	206.5
Operating Margin	11.76%	13.06%	-	7.78%	16.77%	17.25%
Earnings before Tax (EBT) ¹	57.96	93.84	-	54.25	169.4	187.9
Net income ¹	46.28	89.71	130.7	-49.98	100.7	112
Net margin	7.47%	12.29%	-	-4.8%	9.09%	9.35%
EPS ²	0.8578	1.663	2.430	-0.9295	1.867	2.075
Free Cash Flow	21.26	95.32	-	165.4	-	-
FCF margin	3.43%	13.05%	-	15.89%	-	-
FCF Conversion (EBITDA)	19.83%	66.93%	-	141.11%	-	-
FCF Conversion (Net income)	45.93%	106.24%	-	-	-	-
Dividend per Share ²	0.1900	0.1880	-	0.6133	0.8298	1.423
Announcement Date	11/02/20	04/03/21	02/03/23	07/03/24	-	-

¹BRL in Million²BRL

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q1	2023 Q2	2023 Q3	2023 Q4
Net sales	-	-	-	-
EBITDA	-	-	-	-
EBIT	-	-	-	-
Operating Margin	-	-	-	-
Earnings before Tax (EBT)	-	-	-	-
Net income	-	-	-	-
Net margin	-	-	-	-
EPS ¹	-0.0633	-1.309	0.0766	0.3665
Dividend per Share	-	-	-	-
Announcement Date	10/05/23	10/08/23	09/11/23	07/03/24

¹BRL

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2022	2023	2024	2025
Net Debt ¹	238	169	-	128	134	151
Net Cash position ¹	-	-	-	-	-	-
Leverage (Debt/EBITDA)	2.223 x	1.185 x	-	1.092 x	0.6026 x	0.6187 x
Free Cash Flow	21.3	95.3	-	165	-	-
ROE (net income / shareholders' equity)	9.75%	17%	-	-7.01%	14.1%	14.7%
ROA (Net income/ Total Assets)	5.39%	9.09%	-	-3.81%	7.54%	8.02%
Assets ¹	858.6	986.7	-	1,313	1,335	1,396
Book Value Per Share ²	9.120	10.40	-	12.80	13.80	14.40
Cash Flow per Share	-	-	-	-	-	-
Capex	50.4	16.6	-	24.9	-	-
Capex / Sales	8.13%	2.28%	-	2.39%	-	-
Announcement Date	11/02/20	04/03/21	02/03/23	07/03/24	-	-

¹BRL in Million²BRL

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Ouro Fino Saúde Animal Participações S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

18.99 BRL

Average target price

23.5 BRL

Spread / Average Target

+23.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A.	-26.99%	183M
CSL LIMITED	+3.79%	95.71B
SAMSUNG BIOLOGICS CO.,LTD.	+6.58%	41.64B
BIOGEN INC.	-13.20%	32.7B
UCB	+77.57%	28.65B
BIOMARIN PHARMACEUTICAL INC.	-16.02%	15.38B
INCYTE CORPORATION	-8.17%	12.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.49%	11.47B
ALTEOGEN INC.	+162.44%	9.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.92%	9.07B

Biopharmaceuticals